VCs & PE Investors in Biotech: Are you confident in your operational due diligence?
The biggest risk in biotech isn’t always the science—it’s the execution. A brilliant molecule can be destroyed by a flawed protocol, an unrealistic budget, or an underperforming CRO.
Welcome to HYGEIA! We are operational due diligence and portfolio oversight experts for biotech investors. We help investors de-risk their investments by pressure-testing Clinical Development Plans. How?
We provide:
➡️ Pre-deal Due Diligence Sprints
➡️ Interim Leadership for portfolio turnarounds
➡️ Ongoing Portfolio Health & Performance Intelligence
Why can we do this? We speak all three languages:
🔬 The Science: Post-graduate training, Harvard Medical School (Cancer Genomics)
⚙️ The Operations: 20+ years leading global trials & managing $0.5B+ P&Ls at PAREXEL
💸 The Finance: MBA & accredited in Value Investing at Ivey Business School
We’ve helped VCs salvage $35M+ assets and drive successful acquisitions. Now, we’re productizing that expertise for the investment community.
What’s the most common operational red flag you’ve seen in a biotech investment?
#BiotechVC #VentureCapital #DueDiligence #LifeSciences #DrugDevelopment #PortfolioManagement #PrivateEquity #Biotech #ClinicalTrials #OperationalExcellence